UBS Group’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-5,585
| Closed | -$25.3K | – | 10442 |
|
|
2025
Q3 | $25.3K | Sell |
5,585
-8,585
| -61% | -$25.3K | ﹤0.01% | 8012 |
|
|
2025
Q2 | $30.5K | Sell |
14,170
-43,378
| -75% | -$121K | ﹤0.01% | 8148 |
|
|
2025
Q1 | $251K | Buy |
57,548
+9,952
| +21% | +$44.9K | ﹤0.01% | 6380 |
|
|
2024
Q4 | $222K | Buy |
47,596
+35,188
| +284% | +$237K | ﹤0.01% | 6388 |
|
|
2024
Q3 | $87.1K | Buy |
12,408
+6,050
| +95% | +$43.9K | ﹤0.01% | 6455 |
|
|
2024
Q2 | $43.6K | Buy |
6,358
+5,426
| +582% | +$50.5K | ﹤0.01% | 6800 |
|
|
2024
Q1 | $13.2K | Buy |
932
+850
| +1,037% | +$12.9K | ﹤0.01% | 7116 |
|
|
2023
Q4 | $614 | Buy |
82
+2
| +3% | +$18 | ﹤0.01% | 8572 |
|
|
2023
Q3 | $1.2K | Sell |
80
-549
| -87% | -$9.86K | ﹤0.01% | 8049 |
|
|
2023
Q2 | $10K | Sell |
629
-869
| -58% | -$9.14K | ﹤0.01% | 7158 |
|
|
2023
Q1 | $10.7K | Buy |
1,498
+1,418
| +1,773% | +$10K | ﹤0.01% | 7552 |
|
|
2022
Q4 | $464 | Hold |
80
| – | – | ﹤0.01% | 10173 |
|
|
2022
Q3 | $1K | Hold |
80
| – | – | ﹤0.01% | 9908 |
|
|
2022
Q2 | $1K | Sell |
80
-25
| -24% | -$262 | ﹤0.01% | 9801 |
|
|
2022
Q1 | $1K | Sell |
105
-213,159
| -100% | -$3.12M | ﹤0.01% | 9826 |
|
|
2021
Q4 | $3.75M | Sell |
213,264
-101,103
| -32% | -$2.02M | ﹤0.01% | 3151 |
|
|
2021
Q3 | $6.82M | Buy |
314,367
+2,234
| +0.7% | +$57K | ﹤0.01% | 2360 |
|
|
2021
Q2 | $10.9M | Sell |
312,133
-17,506
| -5% | -$943K | ﹤0.01% | 1952 |
|
|
2021
Q1 | $32.5M | Buy |
329,639
+51,153
| +18% | +$6.14M | 0.01% | 1107 |
|
|
2020
Q4 | $30.2M | Buy |
278,486
+187,345
| +206% | +$23.2M | 0.01% | 1087 |
|
|
2020
Q3 | $9.39M | Sell |
91,141
-75,094
| -45% | -$11.2M | ﹤0.01% | 1686 |
|
|
2020
Q2 | $34.7M | Sell |
166,235
-81,158
| -33% | -$14.4M | 0.01% | 779 |
|
|
2020
Q1 | $24.2M | Sell |
247,393
-34,000
| -12% | -$3.96M | 0.01% | 882 |
|
|
2019
Q4 | $32.4M | Buy |
281,393
+53,326
| +23% | +$4.7M | 0.01% | 1039 |
|
|
2019
Q3 | $12.4M | Sell |
228,067
-85,787
| -27% | -$9.67M | ﹤0.01% | 1595 |
|
|
2019
Q2 | $37.3M | Buy |
313,854
+107,454
| +52% | +$8.89M | 0.01% | 824 |
|
|
2019
Q1 | $10.8M | Buy |
206,400
+119,311
| +137% | +$4.82M | ﹤0.01% | 1621 |
|
|
2018
Q4 | $2.74M | Buy |
87,089
+85,107
| +4,294% | +$3.46M | ﹤0.01% | 2713 |
|
|
2018
Q3 | $120K | Buy |
1,982
+585
| +42% | +$32.9K | ﹤0.01% | 5434 |
|
|
2018
Q2 | $74K | Buy |
1,397
+1,140
| +444% | +$68.6K | ﹤0.01% | 5664 |
|
|
2018
Q1 | $15K | Buy |
+257
| New | +$16K | ﹤0.01% | 6606 |
|
|
2017
Q4 | – | Sell |
-179
| Closed | -$6K | – | 7813 |
|
|
2017
Q3 | $6K | Sell |
179
-64
| -26% | -$1.78K | ﹤0.01% | 7130 |
|
|
2017
Q2 | $6K | Buy |
243
+82
| +51% | +$2.24K | ﹤0.01% | 7027 |
|
|
2017
Q1 | $4K | Sell |
161
-388
| -71% | -$11K | ﹤0.01% | 7054 |
|
|
2016
Q4 | $16K | Buy |
549
+148
| +37% | +$4.84K | ﹤0.01% | 6637 |
|
|
2016
Q3 | $17K | Buy |
401
+291
| +265% | +$11K | ﹤0.01% | 6421 |
|
|
2016
Q2 | $3K | Sell |
110
-503
| -82% | -$22.7K | ﹤0.01% | 7308 |
|
|
2016
Q1 | $32K | Buy |
613
+327
| +114% | +$18.3K | ﹤0.01% | 5834 |
|
|
2015
Q4 | $27K | Buy |
286
+246
| +615% | +$21.6K | ﹤0.01% | 6423 |
|
|
2015
Q3 | $3K | Hold |
40
| – | – | ﹤0.01% | 7923 |
|
|
2015
Q2 | $7K | Sell |
40
-3,088
| -99% | -$1.04M | ﹤0.01% | 7672 |
|
|
2015
Q1 | $1.27M | Buy |
+3,128
| New | +$1.32M | ﹤0.01% | 3357 |
|
UBS Group's ADVM Position: Q4 2025 in Review
UBS Group sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 5,585 shares — an estimated $25.3K sold.
UBS Group first reported a position in ADVM in Q1 2015 and held it in 42 quarters. The position peaked at $37.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- UBS Group reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 5,585 Adverum Biotechnologies shares in Q4 2025, an estimated $25.3K.
- UBS Group first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 42 quarters.
- UBS Group's Adverum Biotechnologies position peaked at $37.3M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.